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We investigated the genetic diversity of measles virus 
(MV) in Nigeria (2004–2005) and the Democratic Repub-
lic of the Congo (DRC) (2002–2006). Genotype B3 strains 
circulating in Kinshasa, DRC, in 2002–2003 were fully re-
placed by genotype B2 in 2004 at the end of the second 
Congo war. In Nigeria (2004–2005), two genetic clusters of 
genotype B3, both of which were most closely related to 1 
variant from 1998, were identiﬁ  ed. Longitudinal analysis of 
MV strain diversity in Nigeria suggested that only a few of 
the previously described 1997–1998 variants had continued 
to circulate, but this ﬁ  nding was concomitant with a rapid 
restoration of genetic diversity, probably caused by low vac-
cination coverage and high birth rates. In contrast, the rela-
tively low genetic diversity of MV in DRC and the genotype 
replacement in Kinshasa reﬂ  ect a notable improvement in 
local measles control. 
D
espite >90% reduction in the annual measles mortality 
rate in the World Health Organization (WHO) Afri-
can Region during 2000–2006 (1), measles remains a ma-
jor cause of deaths in children in sub-Saharan Africa (2,3). 
During this period, routine coverage of measles-containing 
vaccines increased from 56% to 73% in this region, and 
>200 million children were vaccinated through supplemen-
tary immunization activities (SIAs) by December 2004 (4). 
In the Democratic Republic of the Congo (DRC), vaccina-
tion coverage with a ﬁ  rst dose of measles vaccine increased 
from 46% in 2000 to 70% in 2005, according to ofﬁ  cial 
country reports (5). The ﬁ  rst major catch-up campaigns 
were conducted in several provinces in 2002 (Kasaï Orien-
tal, Nord Kivu) and 2004 (Kasaï Occidental, Maniema, Ka-
tanga, Maniema, Sud-Kivu) (6). In Nigeria, no SIAs took 
place until 2005, and routine vaccination coverage was per-
sistently low (<40%), at least until 2006 (3,5,7).
Molecular epidemiology has proven to be a major com-
ponent of measles surveillance because it enables the effect 
of accelerated measles control activities to be assessed and 
the elimination of endemic virus strains to be documented. 
In Africa, indigenous measles virus (MV) genotypes seem 
to have a distinct geographic distribution (8,9). In the cen-
tral and western parts of sub-Saharan Africa, mainly clade 
B viruses have been identiﬁ  ed (10–17). The most common 
genotype is B3, with its 2 clusters B3.1 and B3.2 (10). The 
ﬁ  rst B3 sequences in Africa were reported from Nigeria 
(1997–1998). The 41 MV isolates collected in southwest-
ern Nigeria clustered in 2 distinct subgroups of genotype B3 
(B3.1 and B3.2), with an unprecedented maximal sequence 
diversity of 4.6% in the C-terminus of the MV nucleopro-
tein hypervariable region (MVN-HVR) (10). 
In the eastern and southern parts of Africa, genotypes 
D2 and D4 dominated and a new genotype (D10) was 
detected in Uganda in 2000 (8,9,18). Although MV se-
quence data from Africa have been greatly expanded since 
characterization of the ﬁ  rst endemic strains was reported 
(8,10,17,19), essential genetic baseline information is still 
missing from many countries (20). For instance, from 
DRC, only 5 genotype B3 sequences have been reported 
from Kinshasa (2000) (15). We characterized MV strains 
collected during 2002 through 2006 from different loca-
tions throughout DRC and Nigeria. A comparison of the 
genetic diversity of MV strains showed notable differences 
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in epidemiologic patterns in both countries that can be only 
partially explained by differences in vaccination practices.
Materials and Methods
Clinical Specimens and RNA Extraction
Clinical specimens from 84 patients with suspected 
measles were collected in different healthcare centers of 
the National Measles Surveillance Network in DRC dur-
ing 2002–2006. Samples from Kinshasa (n = 53) were 
collected in 14 of the 35 local health districts. Additional 
specimens were obtained from 5 other provinces of DRC: 
Bas-Congo (n = 15), Kasaï Oriental (n = 6), Nord-Kivu (n 
= 2), Sud-Kivu (n = 3), and Maniema (n = 5).
In Nigeria, clinical specimens were collected from pa-
tients with suspected measles in Oyo (n = 16), Lagos (n = 
12), Adamawa (n = 17), Borno (n = 1), and Sokoto (n = 
4) states during 2004 and 2005. Most samples were from 
hospitalized patients, but those from Adamawa State were 
obtained during home visits.
Clinical sample collection and MV isolation on Vero-
SLAM cells were performed as recommended by WHO 
(21). Specimens used for RNA extraction included throat 
swabs (n = 75), oral ﬂ  uid (n = 19), MV culture supernatant 
(n = 19), serum (n = 12), dried blood (n = 5), urine (n = 2), 
and peripheral blood leukocytes (n = 2). Total RNA was 
extracted from 140 μL of body ﬂ  uids, eluted swab speci-
mens, or virus culture supernatant by using the QIAamp 
Viral RNA Kit (QIAGEN, Hilden, Germany). Most mea-
sles cases were also serologically conﬁ  rmed by measles-
speciﬁ  c immunoglobulin M detection by using a commer-
cial ELISA (Enzygnost anti-Measles IgM; Dade-Behring, 
Marburg, Germany). 
Reverse Transcription–PCR and Sequencing
Speciﬁ  c cDNA of MV nucleoprotein was synthesized 
by reverse transcription by using SuperscriptIII Reverse 
Transcriptase (Invitrogen, Merelbeke, Belgium) and ran-
dom hexamers (Invitrogen). MV cDNA was ampliﬁ  ed 
by nested PCR by using primers MN5 (nt 1113–1134, 5′-
GCCATGGGAGTAGGAGTGGAAC-3′ [ 22]) and MN6 
(nt 1773–1754, 5′-CTGGCGGCTGTGTGGACCTG-3′ 
[22]) for the ﬁ  rst round and primers Nf1a (nt 1199–1224, 
5′-CGGGCAAGAGATGGTAAGGAGGTCAG-3′) 
and Nr7a (nt 1725–1703, 5′-AGGGTAGGCGGATGT
TGTTCTGG-3′) for the second round. Both PCRs were 
performed in a total volume of 25 μL that contained 1.8 
mmol/L MgCl2, 1× PCR buffer, 0.2 mmol/L dNTPs, 0.5 
U Platinum Taq (Invitrogen), and 0.8 μmol/L forward and 
reverse primer (Eurogentec, Seraing, Belgium). One mi-
croliter of cDNA or 5 μL of ﬁ  rst-round product (diluted 
50× in water) was added as template. Cycling conditions 
were initial denaturation at 94°C for 2 min; 35 (ﬁ  rst round) 
or 30 (second round) cycles of ampliﬁ  cation at 94°C for 
30s, 55°C (ﬁ  rst round) or 58°C second round) for 1 min, and 
72°C for 1 min; and a ﬁ  nal extension at 72°C for 5 min.
Nested PCR products were puriﬁ   ed by using the 
Jetquick PCR product Puriﬁ   cation Spin Kit (Genomed, 
Lohne, Germany). Twenty-ﬁ  ve cycles of cycle sequenc-
ing (2-min elongation) were performed by using a BigDye 
Terminator version 3.1 Cycle Sequencing kit (Applied Bio-
systems, Nieuwerkerk, the Netherlands) with Nf1a or Nr7a 
primers (0.5 μmol/L) and 10 ng of puriﬁ  ed PCR product. 
Cycle sequencing products were analyzed on an ABI 3130 
Genetic Analyzer (Applied Biosystems). Sequences were 
aligned by using ClustalW (23), and phylogenetic trees 
were constructed by using the neighbor-joining method 
(Kimura 2-parameter) and MEGA4 software (24). All new 
sequences were submitted to GenBank under accession 
nos. FN985102–FN985162.
Results
Kinshasa, DRC, 2002–2003
Eight MV strains collected in Kinshasa during Septem-
ber 2002–January 2003 were assigned to genotype B3.1 on 
the basis of their MVN-HVR sequences (Figure 1). These 
strains were obtained at the peak of a large epidemic that 
occurred in Kinshasa during January 2002–December 2003 
(25). Their sequences differed by only 1 or 2 nt from earlier 
genotype B3.1 variants found in Kinshasa and Brazzaville, 
Congo, in 2000 (15), which suggests that MV continuous-
ly circulated in Kinshasa during 2000–2003, and that the 
overall genetic diversity of strains throughout this outbreak 
was relatively low (0.4% in the MVN-HVR).
Kinshasa, 2004–2006
In 2005, another large measles epidemic with >36,000 
reported cases and >400 deaths occurred in Kinshasa. 
Increasing numbers of cases were reported from the last 
quarter of 2004 until the epidemic peak was reached in 
epidemiologic week 36 in 2005 (Figure 2). Thereafter, the 
incidence steadily decreased and fewer cases were reported 
in the beginning of 2006. Variable numbers of cases were 
reported from the 35 health districts throughout 2005 (Fig-
ure 2), but the case distribution over time suggested 1 large 
epidemic with a variable effect in the different health dis-
tricts in the capital of DRC rather than a series of smaller 
epidemics, as was suggested for the outbreak in 2002–2003 
(25).
MVN-HVR sequences were obtained from 45 strains 
collected in 14 of the 35 health districts of Kinshasa dur-
ing December 2004–February 2006. All 45 viruses be-
longed to genotype B2, and essentially 3 sequence vari-
ants (B2KIN-A, B2KIN-B, and B2KIN-C; Figure 1) were 
identiﬁ   ed. Eleven viruses collected during December 
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2004–May 2005 had identical sequences in the MVN-
HVR (variant B2KIN-A). Five strains collected during 
February–May 2005 corresponded to the second variant 
(B2KIN-B), differing by only 1 nt from B2KIN-A in the 
same gene segment. The third sequence variant (B2KIN-C) 
was ﬁ  rst detected in May 2005 and continued to circulate 
at least until January 2006. This variant differed by 1 and 
2 nts from B2KIN-B and B2KIN-A, respectively, and was 
identiﬁ  ed in 18 strains collected during this period. Eleven 
other sequence variants were obtained, each from 1 patient, 
and all but 1 were collected after the peak of the epidemic. 
Their sequences differed by 1 to 3 nts from B2KIN-C and 
by 2–5 nts from B2KIN-A and B2KIN-B (Figure 1). Thus, 
2 different MV genotypes, B3 and B2, were associated with 
2 consecutive measles epidemics in Kinshasa, suggesting 
that MV circulation had been temporarily interrupted dur-
ing the intraepidemic phase in 2004.
Other DRC Provinces, 2005–2006
Genotype B2 strains detected during 2005 and 2006 in 
Kasaï Oriental, Bas-Congo, and Maniema provinces were 
most closely related to those strains identiﬁ  ed during the 
same period in Kinshasa (Figure 1). MV cases from these 
regions thus seemed to be epidemiologically linked to the 
epidemic in Kinshasa. All 5 sequences obtained from North 
and South Kivu during February–May 2006 were identical 
to B2KIN-A, which was last identiﬁ  ed ≈8 months earlier 
in Kinshasa. In the absence of any information on measles 
incidence in North and South Kivu during 2004–2006, one 
may speculate that B2-KIN-A strains could have been im-
ported from the east into Kinshasa in 2004 but continued to 
circulate at the same time in this region bordering Rwanda. 
Alternatively, B2-KIN-A strains from Kinshasa might have 
been introduced into the region around Lake Kivu at an 
early stage of the epidemic because they were not detected 
after May 2005 in Kinshasa.
Nigeria, 2004–2005
The MVN-HVR sequence was obtained from 58 vi-
ruses collected in 5 states in Nigeria (Oyo, Lagos, Adama-
wa, Borno, Sokoto) during 2005 and 2006. All sequences 
were identiﬁ  ed as genotype B3 and grouped in 2 separate 
clusters (Figure 3) with a minimal genetic distance of 5 nts 
(1.1%) between clusters 1 and 2. Sequence variants of clus-
ter 1 were mainly (81.3%) found in the southwestern states 
(Oyo, Lagos), whereas most cluster 2 strains (70.6%) were 
from northern and northeastern states (Adamawa, Borno, 
Sokoto). Compared with MV sequences obtained in Nige-
ria during 1997–1998 (10), both clusters were most closely 
related to 1 particular strain (MVi/Ibadan.NIE/7.98/3).
The maximal sequence diversity identiﬁ  ed in Lagos, 
Ibadan, Yola, and Mubi ranged from 1.8% to 2.9%, de-
spite collection of specimens in each city within a period of 
<2 months. Seventeen sequence variants, differing by 1–11 
nts (0.22 to 2.4%) from each other, were distinguished 
among 28 MV strains collected in January and February 
2004 in Lagos (2.2% diversity; Lagos State) and Ibadan 
(2.2% diversity; Oyo State) (Figure 3).
Ten sequence variants differing by 1–13 nts (0.2%–
2.9%) were identiﬁ  ed among 17 strains collected in the 
northeastern Nigeria (Adamawa State) in June 2005. Eight 
of these sequence variants were detected in 1 city (Yola) 
during a period of only 2 weeks (2.9% diversity). Another 
cluster 2 strain (MVs/Maiduguri.NIE/02.05/1), which had 
a minimum of a 3-nt difference with strains from Adamawa 
State, was identiﬁ  ed a few months earlier in neighboring 
Borno State. Finally, 4 additional sequence variants (2.7% 
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Figure 1. Phylogenetic tree including genotype B2 and genotype 
B3 of measles virus (MV) strains from the Democratic Republic 
of the Congo 2000–2006, and World Health Organization (WHO) 
reference strains (italics) of the corresponding genotypes and 
some other genotype B2 strains available in GenBank (accession 
numbers in brackets). MV strains were named according to WHO 
nomenclature: MVi/City of isolation.Country/epidemiologic week.
year of isolation/isolate number. Sequences obtained from RNA 
extracted from isolates (MVi) or clinical material (MVs) were 
distinguished. The main genotype B2 variants from Kinshasa 
(B2KIN-A, B2KIN-B, and B2KIN-C) are indicated in boldface. 
Except for B2 strains from Kinshasa, the provinces of Democratic 
Republic of the Congo where strains were collected are indicated 
in brackets. The phylogenetic tree was calculated on the basis of 
the 450-nt region that codes for the C-terminus of the MV N protein 
by using MEGA4 software (24) and the neighbor-joining method 
(Kimura 2-parameter, 1,000 bootstraps). Scale bar indicates 
nucleotide substitutions per site.Measles Virus Strain Diversity, Nigeria and DRC
diversity) were obtained during January 2005 in Sokoto 
State in northwestern Nigeria. Thus, multiple lineages of 
genotype B3 were identiﬁ  ed in Nigeria, similar to the situ-
ation in the late 1990s, indicating that measles continued to 
be highly endemic during the study period.
Discussion
This study compared the genetic diversity of MV in 
2 countries in Africa of similar size during a similar pe-
riod. In Nigeria, all viruses belonged to the same geno-
type (B3.1) and were most closely related to viruses found 
in the same country in 1997–1998 (Figure 3) (10), which 
suggests an uninterrupted endemic transmission of MV in 
Nigeria during 1997–2005. MV strains from 2004–2005 
formed 2 clusters within subgroup B3.1, both of which 
were most closely related to 1 particular variant identi-
ﬁ   ed in Nigeria in 1998 (MVi/Ibadan.NIE/7.98/3). No 
B3.2 strains or descendants of most other B3.1 variants 
from 1997–1998 were detected in 2004–2005, even in 
samples from the same cities (Ibadan, Lagos) (Figure 3). 
In 1997–1998, we observed a genetic diversity of 3.1% in 
Lagos and 4.2% in Ibadan. The phylogeny of the 2004–
2005 strains from Nigeria suggests that the 2004–2005 
diversity was not caused by multiple chains of transmis-
sion sustained since 1997–1998, but by only a few chains 
of transmission paired with a rapid restoration of a high 
genetic diversity (2.2% in both cities). Epidemiologic 
bottlenecks that reduce virus diversity include reduction 
of susceptible persons, low population size and density, 
and seasonality of the disease (15,26–28), but the factors 
that promote viral diversity are less well understood. In 
Nigeria, the population density is high (e.g., ≈24,000 in-
habitants/km2 in Lagos in 2005) and vaccination cover-
age was consistently low at ≈40% throughout the study 
period (3,5,7). Furthermore, measles incidence declined 
suddenly at the start of the rainy season (J.R. Kremer, 
pers. comm.), as was reported for other countries in sub-
Saharan Africa (26). 
The longitudinal analysis of MV strain diversity in Ni-
geria conﬁ  rmed that even in populations in which measles 
is highly endemic, periods with low measles incidence 
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Figure 2. Epidemic curve of measles epidemic in Kinshasa, 
Democratic Republic of the Congo, 2005. Numbers of reported 
measles cases per week are shown by epidemiologic week, and 
measles incidence per week in the 35 health districts of Kinshasa 
is illustrated by gray shading. The periods during which the main 
genotype B2 variants (B2KIN-A, -B, and -C) were identiﬁ  ed  in 
Kinshasa are indicated above the epidemic curve.
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Figure 3. Phylogenetic tree including genotype B3 strains of 
measles virus (MV) from Nigeria collected in 1997–1998 and 
2003–2005 (boldface) and World Health Organization (WHO) 
reference strains of genotypes B3.1, B3.2, and B2 (italics). Measles 
strains were named as indicated in the legend to Figure 1. For all 
strains from 2003–2005, which have been published, the GenBank 
accession number is given in brackets. For all strains from 1997–
1998, NIE had been used as a 3-letter code for the country (10). 
For the more recent strains, the ofﬁ  cial WHO 3-letter code NGA 
was used. The phylogenetic tree was calculated on the basis of 
the 450-nt region that codes for the C-terminus of the MV N protein 
by using MEGA4 software (24) and the neighbor-joining method 
(Kimura 2-parameter, 1,000 bootstraps). Scale bar indicates 
nucleotide substitutions per site.RESEARCH
must occur, during which only a few transmission chains 
are sustained. The rapid restoration of a high genetic di-
versity was probably caused by low vaccination cover-
age, high birth rates and population density, and perhaps 
MV importation from neighboring countries. Phylogenetic 
comparison of genotype B3 strains from Nigeria with those 
from other countries in Africa suggests that transmissions 
of MV between different countries in Africa are frequent 
and that the diversity of this genotype in Nigeria reﬂ  ects the 
overall genetic diversity of B3 in Africa (Figure 4). In con-
trast, a noticeably lower genotype B3 strain diversity was 
found in Sudan during 1997–2000 (1.3% in MVN-HVR) 
and in Burkina Faso in 2001 (1.5%); these ﬁ  ndings were 
attributed to a higher vaccination coverage or more limited 
cross-border movement (in the case of Sudan) (15,17). On 
the other hand, MV strain diversity in Nigeria was simi-
lar to that in the People’s Republic of China (1995–2003), 
where multiple lineages (5.3% diversity in MVN-HVR) of 
1 genotype (H1) co-circulated without obvious geographic 
restriction (29).
In contrast to the situation in Nigeria, where the co-
circulation of different B3 viruses continued for years, in 
Kinshasa, MV circulation was apparently interrupted. The 
B3 lineage that caused the outbreak in 2002–2003 and that 
had been detected in 2000 (15) in Kinshasa had disap-
peared in 2004. Genotype B2 strains, which caused another 
large epidemic in Kinshasa ≈1 year later, seem to have fully 
replaced genotype B3 strains. It is commonly believed that 
≥95% of a population needs to be immune to interrupt MV 
transmission (30). Because measles vaccination coverage 
in Kinshasa was suboptimal (<80%, Ministry of Health, 
DRC) additional epidemiologic constraints must have led 
to the observed genotype replacement (31). The emergence 
in Germany of genotype D7, which had gradually replaced 
the indigenous genotypes C2 and D6 during 1999–2001, 
raised the question of whether genotype D7 strains had a 
selective advantage with respect to cross-neutralizing an-
tibodies acquired through vaccination or natural infection 
with other genotypes (22).
It has been shown in stochastic models that the like-
lihood of genotype replacement increases with vaccina-
tion coverage and frequency of virus importation, but that 
it may also occur by chance (28). Interestingly, the time 
point of genotype replacement in Kinshasa coincides with 
the political reuniﬁ  cation of DRC, after the country had 
been divided into 4 self-governed regions during the sec-
ond Congo war (1998–2003). The emergence of genotype 
B2 in Kinshasa may thus have been caused by the massive 
inﬂ  ux of persons from other provinces where genotype B2 
was circulating. Identiﬁ  cation of B2KIN-A strains in north-
eastern DRC (North and South Kivu provinces) in 2006 
and detection of B2KIN-B strains in neighboring Rwanda 
during late 2005 (S. Smit, pers. comm.) is compatible with 
an importation of genotype B2 from the eastern region of 
DRC into Kinshasa. On the other hand, B2 strains identi-
ﬁ  ed in other provinces seemed to be derived from the epi-
demic strains in Kinshasa. Epidemics in Bas-Congo and 
Kasaï Oriental did not start until ≈1 year after the steady 
increase in measles incidence in Kinshasa, although they 
were connected to the capital by much frequented roads. 
Thus, a vaccination campaign during the early outbreak 
may have prevented many measles cases and deaths not 
only in Kinshasa, but also in the neighboring provinces, as 
has been suggested (32–34).
Genotype B2 was ﬁ  rst reported from Gabon in 1984 
(20) with no similar virus being detected for >15 years. 
Therefore, genotype B2 was considered inactive, until re-
cent variants of this genotype were found in the Central 
African Republic (2000), South Africa (2002), and Angola 
(2003) (13,35). Viruses obtained from these 3 countries 
had a minimum genetic distance of 6–8 nts in the MVN-
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Figure 4. Phylogenetic tree showing a comparison of genotype B3 
strains of measles virus (MV) from Nigeria 1997–1998 and 2003–
2005 (boldface) and representative genotype B3 strains from other 
countries in Africa available in GenBank (accession numbers in 
brackets) and World Health Organization (WHO) reference strains 
of genotypes B3.1, B3.2, and B2 (italics). Naming of MV strains 
and tree calculation were performed on the basis of the 450-nt 
region that codes for the C-terminus of the MV N protein by using 
MEGA4 software (24) and the neighbor-joining method (Kimura 
2-parameter, 1,000 bootstraps). Scale bar indicates nucleotide 
substitutions per site.Measles Virus Strain Diversity, Nigeria and DRC
HVR compared with the closest variant (MVi.Libreville.
GAB/84[R102]) obtained from Gabon almost 20 years ear-
lier. The B2KIN-B variant differed by only 1 nt from the 
closest strain identiﬁ  ed 20 years earlier in Libreville (Ga-
bon, Figure 1). Thus, several lineages of genotype B2 have 
probably circulated continuously in central and southern 
Africa since at least the 1980s, but were never reported be-
cause of suboptimal molecular surveillance. Genotype B2 
may have circulated in DRC and perhaps even in Kinshasa 
long before it was ﬁ  rst detected in 2004. No MV sequences 
were available from DRC before this study, except for a 
few B3 strains from Kinshasa, 2000 (15). However, even if 
we cannot exclude the possibility that genotype B2 was al-
ready present during the 2002–2003 epidemic in Kinshasa, 
B3 seemed to predominate at that time.
Conclusions
The difference in genetic diversity of MV in DRC and 
Nigeria is consistent with the level of disease control in both 
countries during the study period (5). In Nigeria, genotype 
B3 has circulated continuously, at least during 1997–2005. 
Although transmission of most lineages from 1997–1998 
had apparently been interrupted, the genetic diversity ob-
served in 2004–2005 was notable, suggesting that the ge-
netic diversity of MV can rapidly increase in settings with 
low vaccination coverage and high birth rates.
In DRC, MV circulation has probably decreased be-
cause of a notable increase in routine vaccination coverage 
and SIAs in several provinces. However, the emergence 
of genotype B2 in 2004–2006 showed that measles inci-
dence can rapidly rise in settings with high birth rates and 
massive migration of large populations. Of all countries in 
Africa, DRC and Nigeria reported the largest numbers of 
measles cases (12,461 and 9,960) in 2008 and the highest 
average annual measles incidence per 100,000 population 
during 2005–2008, despite the vaccination of >18 million 
(DRC) and 60 million children (Nigeria) during recent 
SIAs (2006–2008) (7). Sequence analysis of more recent 
MV strains from Nigeria and DRC is warranted to evaluate 
whether these SIAs had any effect on MV strain diversity 
in both countries.
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